AMGEN INC Financial Summary

Quick Answer

AMGEN INC reported Total Revenue of $36.75 billion for fiscal year 2025.

AMGEN INC — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $36.75B
+10.0%
$33.42B
+18.6%
$28.19B
+7.1%
$26.32B
+1.3%
$25.98B
+2.2%
$25.42B
+8.8%
Revenue (ASC 606) $36.75B
+10.0%
$33.42B
+18.6%
$28.19B
+7.1%
$26.32B
+1.3%
$25.98B
+2.2%
$25.42B
+8.8%
Net Income $7.71B
+88.5%
$4.09B
-39.1%
$6.72B
+2.5%
$6.55B
+11.2%
$5.89B
-18.9%
$7.26B
-7.4%
Diluted EPS $14.23
+88.2%
$7.56
-39.5%
$12.49
+3.1%
$12.11
+17.8%
$10.28
-16.5%
$12.31
-4.4%
Total Assets $90.59B
-1.4%
$91.84B
-5.5%
$97.15B
+49.2%
$65.12B
+6.5%
$61.16B
-2.8%
$62.95B
+5.4%
Cash and Equivalents $9.13B
-23.8%
$11.97B
+9.4%
$10.94B
+43.5%
$7.63B
-4.5%
$7.99B
+27.5%
$6.27B
+3.8%
Long-Term Debt $50.01B
-11.6%
$56.55B
-10.5%
$63.17B
+69.1%
$37.35B
+12.4%
$33.22B
+1.0%
$32.90B
+22.1%
Stockholders Equity $8.66B
+47.3%
$5.88B
-5.7%
$6.23B
+70.2%
$3.66B
-45.4%
$6.70B
-28.8%
$9.41B
-2.7%
Operating Income $9.08B
+25.1%
$7.26B
-8.1%
$7.90B
-17.4%
$9.57B
+25.2%
$7.64B
-16.4%
$9.14B
-5.5%
Shares Outstanding 538.80M
+0.4%
536.90M
+0.3%
535.40M
+0.3%
534.00M
-4.4%
558.30M
-3.5%
578.30M
-2.2%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $9.56B +12.4% +4.1%
Revenue (ASC 606) September 30, 2025 $9.56B +12.4% +4.1%
Net Income September 30, 2025 $3.22B +13.6% +124.6%
Diluted EPS September 30, 2025 $5.93 +13.6% +123.8%
Total Assets September 30, 2025 $90.14B -0.8% +2.6%
Cash and Equivalents September 30, 2025 $9.45B +4.8% +17.7%
Long-Term Debt September 30, 2025 $52.43B -7.8% -2.5%
Stockholders Equity September 30, 2025 $9.62B +27.8% +29.5%
Operating Income September 30, 2025 $2.53B +23.4% -4.9%
Shares Outstanding September 30, 2025 538.50M +0.2% +0.0%
  • AMGEN INC reported Total Revenue of $36.75 billion for fiscal year 2025.
  • AMGEN INC showed an increase of +10.0% in Total Revenue compared to the prior fiscal year.
  • AMGEN INC reported Revenue (ASC 606) of $36.75 billion for fiscal year 2025.
  • AMGEN INC showed an increase of +10.0% in Revenue (ASC 606) compared to the prior fiscal year.
  • AMGEN INC reported Net Income of $7.71 billion for fiscal year 2025.
  • AMGEN INC showed an increase of +88.5% in Net Income compared to the prior fiscal year.
  • AMGEN INC reported Diluted EPS of $14.23 per share for fiscal year 2025.
  • AMGEN INC showed an increase of +88.2% in Diluted EPS compared to the prior fiscal year.
  • AMGEN INC reported Total Assets of $90.59 billion for fiscal year 2025.
  • AMGEN INC showed a decrease of -1.4% in Total Assets compared to the prior fiscal year.
  • AMGEN INC reported Cash and Equivalents of $9.13 billion for fiscal year 2025.
  • AMGEN INC showed a decrease of -23.8% in Cash and Equivalents compared to the prior fiscal year.
  • AMGEN INC reported Long-Term Debt of $50.01 billion for fiscal year 2025.
  • AMGEN INC showed a decrease of -11.6% in Long-Term Debt compared to the prior fiscal year.
  • AMGEN INC reported Stockholders Equity of $8.66 billion for fiscal year 2025.
  • AMGEN INC showed an increase of +47.3% in Stockholders Equity compared to the prior fiscal year.
  • AMGEN INC reported Operating Income of $9.08 billion for fiscal year 2025.
  • AMGEN INC showed an increase of +25.1% in Operating Income compared to the prior fiscal year.
  • AMGEN INC reported Shares Outstanding of 538.80 million shares for fiscal year 2025.
  • AMGEN INC showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment